The U.S. Consulate General in Istanbul welcomed a delegation of nine leading American companies in the fields of genomics, genetics, and precision medicine to Türkiye this week for a trade mission aimed at exploring collaboration opportunities in Türkiye’s rapidly advancing healthcare sector.
During their visit, the companies participated in business-to-business (B2B) meetings with Turkish biopharma companies, research institutes, hospitals, and healthcare startups. The delegation also visited the Health Institutes of Turkey (TÜSEB), the leading biotechnology institute of Türkiye, to learn about the institute and the support it gives to genomic research in Türkiye.
The visiting U.S. companies include: Chapter Dx, Covaris, Exact Sciences, Galatea Bio, Golden Helix, Guardant Health, Labcorp, New England Biolabs, and Redbud Labs.
These companies are global leaders in areas such as:
- Early cancer detection and diagnosis
- Personalized medicine tailored to a patient’s genetic profile
- Advanced tools for genome sequencing and data analysis
- Innovative testing technologies for rare diseases and women’s health
- Smart laboratory solutions to speed up biomedical research
With their cutting-edge technologies and solutions, these U.S. firms are well-positioned to support Türkiye’s national health goals—whether by enhancing early disease detection, expanding access to personalized treatments, or strengthening local research capacity in genomics and biotechnology.
“This trade mission reflects our strong belief in the excellence of American science and innovation,” said U.S. Consul General Julie Eadeh, who hosted the delegation at her residence. “We are proud to support these U.S. companies find new business opportunities as they connect with Türkiye’s impressive health institutions, research networks, and private sector leaders.”
Türkiye is preparing to make a new breakthrough in solar cell production. This development has created great excitement in the sector.
The trade mission was organized by the U.S. Commercial Service, the export promotion arm of the U.S. government. It demonstrates the United States’ commitment to deepening bilateral cooperation in health innovation, medical technology, and the life sciences.
